Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line

Journal of Biological Chemistry

Volumn 291, Issue 7, 2016, Pages 3508-3519

  Ruscica, Massimiliano ^a   Ricci, Chiara ^a   Macchi, Chiara ^a   Magni, Paolo ^a   Cristofani, Riccardo ^a   Liu, Jingwen ^b   Corsini, Alberto ^a,c   Ferri, Nicola ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; FATTY ACIDS; INSULIN; PHOSPHORYLATION; PROTEINS; VEGETABLE OILS;

CONCENTRATION-DEPENDENT MANNERS; INSULIN RECEPTOR SUBSTRATE 1; PRO-INFLAMMATORY CYTOKINES; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT-BINDING PROTEINS; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTORS; VERY LOW DENSITY LIPOPROTEINS;

CELL SIGNALING;

ACYL COENZYME A DESATURASE; APOLIPOPROTEIN B; CHOLESTEROL; FATTY ACID SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; JANUS KINASE; KEXIN; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUBTILISIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYBRID PROTEIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; RECOMBINANT PROTEIN; SOCS3 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; GENE ACTIVATION; GENE OVEREXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RETROVIRUS INFECTION; RNA STABILITY; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE DELIVERY SYSTEM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; HEP-G2 CELL LINE; LIVER CELL; METABOLISM; MUTATION; OBESITY; PHOSPHORYLATION; PROTEIN PROCESSING; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ENZYME INDUCTION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; JANUS KINASES; LIPOGENESIS; MALE; MICE, INBRED C57BL; MUTATION; OBESITY; PHOSPHORYLATION; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964446507     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.664706     Document Type: Article

References (54)

1. Galic, S., Sachithanandan, N., Kay, T. W., and Steinberg, G. R. (2014) Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. Biochem. J. 461, 177-188.
2. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., Akira, S., and Kishimoto, T. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929.
3. Emanuelli, B., Peraldi, P., Filloux, C., Sawka-Verhelle, D., Hilton, D., and Van Obberghen, E. (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275, 15985-15991.
4. Bjørbaek, C., El-Haschimi, K., Frantz, J. D., and Flier, J. S. (1999) The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 274, 30059-30065.
5. Steppan, C. M., Wang, J., Whiteman, E. L., Birnbaum, M. J., and Lazar, M. A. (2005) Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25, 1569-1575.
6. Ueki, K., Kondo, T., and Kahn, C. R. (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434-5446.
7. Ueki, K., Kondo, T., Tseng, Y. H., and Kahn, C. R. (2004) Central role of suppressorsofcytokinesignalingproteinsinhepaticsteatosis, insulinresistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. U.S.A. 101, 10422-10427.
8. Elam, M. B., Yellaturu, C., Howell, G. E., Deng, X., Cowan, G. S., Kumar, P., Park, E. A., Hiler, M. L., Wilcox, H. G., Hughes, T. A., Cook, G. A., and Raghow, R. (2010) Dysregulation of sterol regulatory element binding protein- 1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription- 1 signaling. Metab. Clin. Exp. 59, 587-598.
9. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug. Discov. 11, 367-383.
10. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156.
11. Ferri, N., Corsini, A., Macchi, C., Magni, P., and Ruscica, M. (2015) Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: Experimental animal models and clinical evidence. Transl. Res. 10.1016/j.trsl.2015.10.004.
12. Ferri, N., Tibolla, G., Pirillo, A., Cipollone, F., Mezzetti, A., Pacia, S., Corsini, A., and Catapano, A. L. (2012) Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 220, 381-386.
13. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282, 20799-20803.
14. Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., and Breslow, J. L. (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44, 2109-2119.
15. Guo, Y. L., Liu, J., Xu, R. X., Zhu, C. G., Wu, N. Q., Jiang, L. X., and Li, J. J. (2013) Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin. Drug Investig. 33, 877-883.
16. Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., and Konrad, R. J. (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49, 394-398.
17. Huijgen, R., Boekholdt, S. M., Arsenault, B. J., Bao, W., Davaine, J. M., Tabet, F., Petrides, F., Rye, K. A., DeMicco, D. A., Barter, P. J., Kastelein, J. J., and Lambert, G. (2012) Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: A nested case-control study. J. Am. Coll. Cardiol. 59, 1778-1784.
18. Goldstein, J. L., DeBose-Boyd, R. A., and Brown, M. S. (2006) Protein sensors for membrane sterols. Cell 124, 35-46.
19. Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002) SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.
20. Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., and Goldstein, J. L. (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U.S.A. 100, 12027-12032.
21. Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., and Davignon, J. (2010) A new method for measurement of total plasma PCSK9: clinical applications. J. Lipid Res. 51, 140-149.
22. Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A. L., Grefhorst, A., Staels, B., and Krempf, M. (2006) Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory elementbinding protein 1c. J. Biol. Chem. 281, 6211-6218.
23. Jeong, H. J., Lee, H. S., Kim, K. S., Kim, Y. K., Yoon, D., and Park, S. W. (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 49, 399-409.
24. Cariou, B., Langhi, C., Le Bras, M., Bortolotti, M., Lê, K. A., Theytaz, F., Le May, C., Guyomarc'h-Delasalle, B., Zaïr, Y., Kreis, R., Boesch, C., Krempf, M., Tappy, L., and Costet, P. (2013) Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutrition Metabolism 10, 4.
25. Lakoski, S. G., Lagace, T. A., Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94, 2537-2543.
26. Alborn, W. E., Cao, G., Careskey, H. E., Qian, Y. W., Subramaniam, D. R., Davies, J., Conner, E. M., and Konrad, R. J. (2007) Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53, 1814-1819.
27. Baass, A., Dubuc, G., Tremblay, M., Delvin, E. E., O'Loughlin, J., Levy, E., Davignon, J., and Lambert, M. (2009) Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 55, 1637-1645.
28. Garton, K. J., Ferri, N., and Raines, E. W. (2002) Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. Biotechniques 32, 830.
29. Ferri, N., Garton, K. J., and Raines, E. W. (2003) An NF-kappaB-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells. J. Biol. Chem. 278, 19757-19764.
30. Greco, C. M., Camera, M., Facchinetti, L., Brambilla, M., Pellegrino, S., Gelmi, M. L., Tremoli, E., Corsini, A., and Ferri, N. (2012) Chemotactic effect of prorenin on human aortic smooth muscle cells: A novel function of the (pro)renin receptor. Cardiovasc. Res. 95, 366-374.
31. Ferri, N., Colombo, G., Ferrandi, C., Raines, E. W., Levkau, B., and Corsini, A. (2007) Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler. Thromb. Vasc. Biol. 27, 1043-1049.
32. Corsini, A., Verri, D., Raiteri, M., Quarato, P., Paoletti, R., and Fumagalli, R. (1995) Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25- hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler. Thromb. Vasc. Biol. 15, 420-428.
33. Li, H., Dong, B., Park, S. W., Lee, H. S., Chen, W., and Liu, J. (2009) Hepatocyte nuclear factor 1- plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound ber-berine. J. Biol. Chem. 284, 28885-28895.
34. Norata, G. D., Banfi, C., Pirillo, A., Tremoli, E., Hamsten, A., Catapano, A. L., and Eriksson, P. (2004) Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br. J. Haematol 127, 97-104.
35. Kamisuki, S., Mao, Q., Abu-Elheiga, L., Gu, Z., Kugimiya, A., Kwon, Y., Shinohara, T., Kawazoe, Y., Sato, S., Asakura, K., Choo, H. Y., Sakai, J., Wakil, S. J., and Uesugi, M. (2009) A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882-892.
36. Masciocchi, D., Villa, S., Meneghetti, F., Pedretti, A., Barlocco, D., Legnani, L., Toma, L., Kwon, B. M., Nakano, S., Asai, A., and Gelain, A. (2012) Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors. MedChemComm 3, 592-599.
37. Giunzioni, L., Tavori, H., Covarrubias, R., Major, A. S., Ding, L., Zhang, Y., DeVay, R. M., Hong, L., Fan, D., Predazzi, I. M., Rashid, S., Linton, M. F., and Fazio, S. (2015) Local Effects of Human PCSK9 on the Atherosclerotic Lesion. J. Pathol. 10.1002/path.4630.
38. Pellegrino, S., Ferri, N., Colombo, N., Cremona, E., Corsini, A., Fanelli, R., Gelmi, M. L., and Cabrele, C. (2009) Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. Bioorg. Med. Chem. Lett. 19, 6298-6302.
39. Pirvulescu, M., Manduteanu, I., Gan, A. M., Stan, D., Simion, V., Butoi, E., Calin, M., and Simionescu, M. (2012) A novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation. Biochem. Biophys. Res. Commun. 422, 321-326.
40. Melone, M., Wilsie, L., Palyha, O., Strack, A., and Rashid, S. (2012) Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol. 59, 1697-1705.
41. Chorba, J. S., and Shokat, K. M. (2014) The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J. Biol. Chem. 289, 29030 -29043.
42. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. (1993) Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science 259, 87-91.
43. Torisu, T., Sato, N., Yoshiga, D., Kobayashi, T., Yoshioka, T., Mori, H., Iida, M., and Yoshimura, A. (2007) The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12, 143-154.
44. Adorni, M. P., Favari, E., Ronda, N., Granata, A., Bellosta, S., Arnaboldi, L., Corsini, A., Gatti, R., and Bernini, F. (2011) Free cholesterol alters macrophage morphology and mobility by an ABCA1-dependent mechanism. Atherosclerosis 215, 70-76.
45. Cui, Y., Huang, L., Elefteriou, F., Yang, G., Shelton, J. M., Giles, J. E., Oz, O. K., Pourbahrami, T., Lu, C. Y., Richardson, J. A., Karsenty, G., and Li, C. (2004) Essential role of STAT3 in body weight and glucose homeostasis. Mol. Cell. Biol. 24, 258-269.
46. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N. G. (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and posttranslational modifications. J. Biol. Chem. 281, 30561-30572.
47. Ouguerram, K., Chetiveaux, M., Zair, Y., Costet, P., Abifadel, M., Varret, M., Boileau, C., Magot, T., and Krempf, M. (2004) Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24, 1448-1453.
48. Sun, H., Samarghandi, A., Zhang, N., Yao, Z., Xiong, M., and Teng, B. B. (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein b and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32, 1585-1595.
49. Rashid, S., Tavori, H., Brown, P. E., Linton, M. F., He, J., Giunzioni, I., and Fazio, S. (2014) Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 130, 431-441.
50. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., and Prat, A. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459.
51. Shende, V. R., Wu, M., Singh, A. B., Dong, B., Kan, C. F., and Liu, J. (2015) Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1- in normolipidemic mice. J. Lipid Res. 56, 801-809.
52. Cao, A., Wu, M., Li, H., and Liu, J. (2011) Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J. Lipid Res. 52, 518-530.
53. Emanuelli, B., Peraldi, P., Filloux, C., Chavey, C., Freidinger, K., Hilton, D. J., Hotamisligil, G. S., and Van Obberghen, E. (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor- - in the adipose tissue of obese mice. J. Biol. Chem. 276, 47944-47949.
54. Roubtsova, A., Munkonda, M. N., Awan, Z., Marcinkiewicz, J., Chamberland, A., Lazure, C., Cianflone, K., Seidah, N. G., and Prat, A. (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31, 785-791.